When judging whether a GLP-1 is worth the cost, the monthly drug bill leaves out the chance of reaching the treatment goal. A UK analysis divided annual pharmacy cost by the proportion of patients who hit a composite target. The result estimates the cost per patient who reached that target [1].
The targets combined glycemic control at two thresholds with weight loss at 5%, 10% or 15%, and required avoiding hypoglycemia. Response rates came from a post-hoc cut of the SURPASS-2 trial (n = 1,845), in which both groups took metformin. The analysis used UK pharmacy prices, including the tirzepatide costs NICE appraised in TA924. At the strictest combination, HbA1c at or below 6.5% with weight loss of at least 15% and no hypoglycemia, tirzepatide cost £5,650, £8,665 and £9,462 less per patient reaching it at the 5, 10 and 15 mg doses respectively.
The pattern inside that result is more interesting than the headline. Differences grew as targets got stricter, which is what happens when one drug produces more large responses: the denominator shrinks faster for the weaker performer. And the pattern reversed at the loosest target, where HbA1c below 7.0% with 5% weight loss and no hypoglycemia was cheaper per responder on semaglutide [1]. The cost per responder depends on which endpoint the analysis uses.
The figures use UK pharmacy costs, including the tirzepatide prices appraised by NICE. They cannot tell a U.S. patient what they would pay. Several authors list Eli Lilly affiliations, and the results rely on a post hoc analysis of a single trial [1].
The tirzepatide lifetime cost model asks a longer-term question than this trial-based comparison. Read the assumptions before using its projections to compare costs.
A separate study of tirzepatide and semaglutide at other doses measured short-term weight change. An analysis of cost per quality-adjusted life year illustrates how economic models can account for both length and quality of life.